Vigil Neuroscience, Inc. (VIGL)

NASDAQ: VIGL · IEX Real-Time Price · USD
10.99
+0.16 (1.48%)
Nov 25, 2022 4:30 PM EDT - Market closed
1.48%
Market Cap 385.34M
Revenue (ttm) n/a
Net Income (ttm) -62.83M
Shares Out 33.30M
EPS (ttm) -6.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,187
Open 10.45
Previous Close 10.83
Day's Range 10.26 - 11.41
52-Week Range 2.18 - 18.27
Beta n/a
Analysts Buy
Price Target 20.40 (+85.6%)
Earnings Date Nov 14, 2022

About VIGL

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystroph... [Read more]

Industry Biotechnology
IPO Date Jan 7, 2022
Employees 52
Stock Exchange NASDAQ
Ticker Symbol VIGL
Full Company Profile

Analyst Forecast

According to 12 analysts, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is 20.4, which is an increase of 85.62% from the latest price.

Price Target
$20.4
(85.62% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update

–Announced interim topline data from Phase 1 trial of VGL101 in healthy volunteers–

2 weeks ago - GlobeNewsWire

Vigil Neuroscience to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ne...

2 weeks ago - GlobeNewsWire

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Hea...

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ne...

3 weeks ago - GlobeNewsWire

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ne...

3 weeks ago - GlobeNewsWire

7 Short-Squeeze Stocks to Buy for Contrarian Investors

Short-squeeze stocks offer tremendous upside potential for people who laugh in the face of danger. Fundamentally, the concept involves betting against the pessimistic crowd with the aim of sparking a re...

1 month ago - InvestorPlace

Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know

The consensus price target hints at a 121.3% upside potential for Vigil Neuroscience, Inc. (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

2 months ago - Zacks Investment Research

Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of n...

2 months ago - GlobeNewsWire

How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%

The consensus price target hints at a 132.7% upside potential for Vigil Neuroscience, Inc. (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

2 months ago - Zacks Investment Research

Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade

The mean of analysts' price targets for Vigil Neuroscience, Inc. (VIGL) points to a 166.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

3 months ago - Zacks Investment Research

Vigil Neuroscience Announces $75 Million Private Placement Financing

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ne...

3 months ago - GlobeNewsWire

Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update

– Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia –

3 months ago - GlobeNewsWire

Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ne...

3 months ago - GlobeNewsWire

Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and ...

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ne...

3 months ago - GlobeNewsWire

7 No-Brainer Biotech Stocks to Add to Your Buy List

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on...

Other symbols: BIIBCINCCRSPEBSHRMY
5 months ago - InvestorPlace

Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday

We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted ...

5 months ago - InvestorPlace

Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia

- Received approval from the Human Research Ethics Committee in Australia to initiate a Phase 1 trial of VGL101 in healthy volunteers at doses above 20 mg/kg -

5 months ago - GlobeNewsWire

Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights

- Presented key findings enhancing clinical understanding of ALSP at the 2022 American Academy of Neurology Annual Meeting -

6 months ago - GlobeNewsWire

Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

- Completed successful initial public offering, raising $98 million in gross proceeds -

8 months ago - GlobeNewsWire

Vigil Neuroscience to Present at Stifel 2022 CNS Days

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of n...

8 months ago - GlobeNewsWire

Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology A...

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of n...

8 months ago - GlobeNewsWire

New Year, Fresh Stocks: 3 IPOs That Joined the Market in January

Should you add these stocks to your portfolio?

Other symbols: AMLXCINC
9 months ago - The Motley Fool

Vigil Neuroscience Announces Closing of Initial Public Offering

CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ne...

10 months ago - GlobeNewsWire

The Year's First Three IPOs All Went 'Clunk.' This Is Why.

Amylyx Pharmaceuticals raised $190 million, CinCor Pharma collected nearly $194 million, and Vigil Neuroscience came in at $98 million.

Other symbols: AMLXCINC
10 months ago - Barrons

Three Biotech IPOs Started Trading. Here's How the Stocks Did.

Amylyx Pharmaceuticals raised $190 million, CinCor Pharma collected nearly $194 million, and Vigil Neuroscience came in at $98 million.

Other symbols: AMLXCINC
10 months ago - Barrons

Vigil Neuroscience Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ne...

10 months ago - GlobeNewsWire